Cancer Research Funding

Current Funding Opportunities

MCW Cancer Center Pilot Funding Program

November 2017 RFA

LOI deadline passed. Full application due Jan. 17

Marquette + MCWCC Multi-PI Grant RFA

LOI deadline passed.  Full application due Dec. 28

Grant support resources are now available from the MCW Cancer Center.

National Cancer Institute (NCI)

Open AllClose All
  Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01) (Deadline: 2/15/18)

Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01)

This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), encourages the submission of grant applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO-screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.

Applications due February 15, 2018

  Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Optional) (Deadline: 2/16/18)

Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Optional)

The purpose of this funding opportunity announcement (FOA) is twofold: 1. to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2. to understand the underlying mechanisms of their action(s), and variability in responses to these interventions.

This FOA calls for interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including, but not limited to: nutritional science, microbiology, virology, microecology and microbiome, genomics, immunology, computational biology, chemistry, bioengineering, as well as integration of omics and computational approaches in DNA technologies.

This FOA will not support phase III clinical trials.

Applications due February 16, 2018

  Developing Interventions for Health-Enhancing Physical Activity (R21/R33 - Clinical Trial Optional) (Deadline: 2/16/18)

Developing Interventions for Health-Enhancing Physical Activity (R21/R33 - Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to fund highly innovative and promising research aimed at developing multi-level physical activity intervention programs acting on at least two levels of the socioecological model and designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation. This FOA provides support for up to two years (R21 phase) for research planning activities and feasibility studies, followed by a possible transition to expanded research support (R33 phase) for optimizing the intervention and conducting larger-scale feasibility studies. Transition to the R33 depends on the completion of applicant-defined milestones, as well as program priorities and the availability of funds.

Applications due February 16, 2018

  Examination of Survivorship Care Planning Efficacy and Impact (R21) (Deadline: 2/16/18)

Examination of Survivorship Care Planning Efficacy and Impact (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate developmental research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening, and health behavior guidelines; utilization of follow-up care; survivors' health and psychosocial outcomes. How organizational-level factors influence the implementation of care planning and its associated costs is also of interest. Specifically, the FOA aims to stimulate research that will: 1) develop and test metrics for evaluating the impact of survivorship care planning; 2) evaluate the impact of survivorship care planning on cancer survivors' morbidity, self-management and adherence to care recommendations, utilization of follow-up care; 3) evaluate effects of planning on systems outcomes, such as associated costs and impact on providers and organizations implementing the care planning; and 4) identify models and processes of care that promote effective survivorship care planning. The ultimate goal of this FOA is to generate a body of science that will inform the development and delivery of interventions that improve follow-up care for cancer survivors.

Applications due February 16, 2018

  Biological Comparisons in Patient-Derived Models of Cancer (U01) (Deadline: 3/7/18)

Biological Comparisons in Patient-Derived Models of Cancer (U01)

The purpose of this FOA is to encourage applications wherein similarities and differences in the underlying biological mechanisms that drive cancer phenotype and response to perturbations between two or more patient-derived models of cancer originating from a common patient sample are delineated and compared.

Applications due March 7, 2018

  Notice of Intent to Publish a Funding Opportunity Announcement for ‘Programs to Increase Diversity among Individuals Engaged in Health Related Research’ (PRIDE) Summer Institutes (R25)/(U24) (Deadline: FOA December 2017 (expected); Due date March 2018)

Notice of Intent to Publish a Funding Opportunity Announcement for ‘Programs to Increase Diversity among Individuals Engaged in Health Related Research’ (PRIDE) Summer Institutes (R25)/(U24)

The National Heart, Lung, and Blood Institute intends to publish a Funding Opportunity Announcement (FOA) to solicit applications for the Programs to Increase Diversity among Individuals Engaged in Health Related Research (PRIDE) Summer Institutes. The PRIDE Summer Institutes programs aim to enhance the diversity of the biomedical, behavioral and clinical research workforce through provision of research education and mentoring experiences for junior faculty from underrepresented backgrounds, at NHLBI-funded summer institutes across the nation.

This Notice is being provided to allow potential applicants sufficient time to develop responsive applications. The FOA is expected to be published in December 2017 with an application due date in March 2018 and will utilize the R25 mechanism. Details of this planned FOA are provided below.

FOA Expected Release Date: December 2017 with a due date of March 2018

  Request for Proposals in Leukemia Research (Deadline: 4/1/18)

Request for Proposals in Leukemia Research

This request for proposals (RFP) is to solicit innovative research in leukemia. Grants are offered to those requesting support for laboratory, translational, or clinical research related to acute leukemia. The Foundation is supporting leukemia research because it recognizes that significant advances in the understanding, diagnosis, and treatment of leukemia are needed to achieve the goal of "when everyone survives."

Applications due April 1, 2018

  Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (R43/R44 Clinical Trial Not Allowed) (Deadline: 4/5/18)

Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (R43/R44 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research for commercial development of novel cancer-relevant technologies. The proposed research projects are expected to focus on the development of highly-innovative technologies that improve molecular and/or cellular analysis of cancer with a significant likelihood for either overcoming persistent challenges or obstacles or opening entirely new fields for cancer research or clinical care.

Applications should specify milestones relevant to both the development and commercialization of these technologies. This FOA complements the goals of the NCI's Innovative Molecular Analysis Technologies (IMAT) program by facilitating the path towards technology commercialization. Prior participation in the IMAT Program is not required for eligibility for this FOA. Applications are expected to indicate the significant attributes and advantages of the proposed technology over currently available technologies and conventional approaches.

Clinical trials are not allowed for this FOA.

Applications due April 5, 2018

  The Pancreatic Cancer Detection Consortium (U01) (Deadline: 4/6/18)

The Pancreatic Cancer Detection Consortium (U01)

This Funding Opportunity Announcement (FOA) invites applications from multi-disciplinary teams of researchers and clinicians to establish the Pancreatic Cancer Detection Consortium (PCDC) to conduct research to improve the detection of early stage pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions. This initiative addresses one of the four research priorities identified in the National Cancer Institute's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma.

The PCDC is intended to support research for the development and testing of new molecular and imaging biomarkers for identifying patients at high risk for PDAC (because of genetic factors or the presence of precursor lesions) who could be candidates for early intervention. The research will be conducted by individual multi-disciplinary research teams, hereafter called Units.

The Units will undertake studies on the following areas:

  • Identification and testing of biomarkers measurable in bodily fluids for early detection of PDAC or its precursor lesions;
  • Determine which pancreatic cysts are likely to progress to cancer;
  • Develop molecular- and/or imaging-based approaches for screening populations at high risk of PDAC;
  • Conduct biomarker validation studies; and
  • Collect longitudinal biospecimens for the establishment of a biorepository.

All Units are expected to participate in collaborative activities with other Units and share ideas, specimens and data within the Consortium.

Applications due September 21, 2017 OR April 6, 2018

  Opportunities for Collaborative Research at the NIH Clinical Center (U01) (Deadline: 4/11/18)

Opportunities for Collaborative Research at the NIH Clinical Center (U01)

The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications that improve health. It encourages high quality science demonstrating the potential to result in understanding an important disease process or lead to new therapeutic interventions, diagnostics, or prevention strategies within the research interests and priorities of the participating NIH Institutes/Centers (ICs).

Specifically, the program seeks to broaden and strengthen translational research collaborations between basic and clinical researchers both within and outside NIH to accelerate and enhance translational science by promoting partnerships between NIH intramural investigators (e.g., those conducting research within the labs and clinics of the NIH) and extramural investigators (e.g., those conducting research in labs outside the NIH), and by providing support for extramural investigators to take advantage of the unique research opportunities available at the NIH Clinical Center by conducting research projects in collaboration with NIH intramural investigators.

In order to be eligible for this program, the application must include at least one intramural scientist as Program Director/Principal Investigator or collaborator, and at least some of the research must be conducted at the NIH Clinical Center. Through this collaboration, external researchers may gain access to the NIH Clinical Center and leverage the diverse Clinical Center resources, expertise, and infrastructure available to test promising laboratory- and animal-based discoveries with potential for advancing disease diagnosis, treatment and prevention. The special environment of the Clinical Center can support studies that may not be readily supported elsewhere. This may include collaborations that propose targeted increases in new patients enrolled in protocols at the Clinical Center.

The companion FOA (PAR-15-286) encourages X02 pre-applications for Opportunities for Collaborative Research at the NIH Clinical Center. The X02 pre-application is the recommended (not required) first step in the application process for this FOA. Potential applicants should read both FOAs. Investigators whose X02 pre-applications are meritorious, can be accommodated by the resources of the NIH Clinical Center and the relevant intramural program, and align with the research missions of the participating NIH Institutes, will be notified of the opportunity to submit a U01 application to this FOA.

Deadline: April 11, 2018

  High or Medium Priority AIDS Research on Non-AIDS-Defining or AIDS-Defining Cancers (R01) (Deadlines: 1/7/18; 5/7/18)

High or Medium Priority AIDS Research on Non-AIDS-Defining or AIDS-Defining Cancers (R01)

The purpose of this funding opportunity announcement (FOA) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency (HIV) infection or acquired immunodeficiency syndrome (AIDS), particularly the non-AIDS defining malignancies which are now a leading cause of death in HIV-infected individuals.

This FOA encourages high or medium priority AIDS research in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both non-AIDS defining and AIDS-defining malignancies in populations with an underlying HIV infection.

This FOA encourages research efforts that will identify specific contributions resulting from HIV infection and its potential interaction with other pathogens for the development and pathogenesis of these cancers; and provide information on the clinical outcomes of such cancers in the HIV-infected population. Ultimately, such efforts could inform screening approaches and therapies targeted to the HIV-infected population.

Components of Participating Organizations:

  • National Cancer Institute (NCI)
  • National Institute of Dental and Craniofacial Research (NIDCR)

Applications due January 7, 2018; May 7, 2018

  "High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R21) (Deadlines: 1/7/18; 5/7/18)

"High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R21)

The purpose of this funding opportunity announcement (FOA) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency (HIV) infection or acquired immunodeficiency syndrome (AIDS), particularly the non-AIDS defining malignancies which are now a leading cause of death in HIV-infected individuals.

This FOA encourages high or medium priority AIDS research in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both non-AIDS defining and AIDS-defining malignancies in populations with an underlying HIV infection.

This FOA encourages research efforts that will (i) identify specific contributions resulting from HIV infection and its potential interaction with other pathogens for the development and pathogenesis of these cancers and (ii) provide information on the clinical outcomes of such cancers in the HIV-infected population. Ultimately, such efforts could inform screening approaches and therapies targeted to the HIV-infected population.

Applications due January 7, 2018; May 7, 2018

  Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) (Deadline: 5/14/18)

Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)

The purpose of this funding opportunity announcement (FOA) is to encourage exploratory developmental research to improve Native American (NA) health. Such research can include: conducting secondary analysis of existing data (such as databases that the Tribal Epidemiology Centers have collected); merge various sources of data to answer critical research questions; conduct pilot and feasibility studies; and/or assess and validate measures that are being developed and/or adapted for use in NA communities.

For the purposes of this FOA, the term 'Native Americans' includes the following populations: Alaska Native, American Indian, and Native Hawaiian. The term 'Native Hawaiian' means any individual whose ancestors were natives, prior to 1778, belonging to the area that now comprises the State of Hawaii.

Studies should: be culturally appropriate and result in promoting the adoption of healthy lifestyles; improve behaviors and social conditions and/or improve environmental conditions related to chronic disease; prevent or reduce the consumption of tobacco, alcohol, and other drugs; improve mental health outcomes; reduce risk of HIV infection; improve treatment adherence and/or health-care systems adopting standards of care to improve overall quality of life.

Applications due May 14, 2018

  Research to Improve Native American Health (R21 Clinical Trials Optional) (Deadline: 5/14/18)

Research to Improve Native American Health (R21 Clinical Trials Optional)

The purpose of this funding opportunity announcement (FOA) is to encourage exploratory developmental research to improve Native American (NA) health. Such research can include: conducting secondary analysis of existing data (such as databases that the Tribal Epidemiology Centers have collected); merge various sources of data to answer critical research questions; conduct pilot and feasibility studies; and/or assess and validate measures that are being developed and/or adapted for use in NA communities.

For the purposes of this FOA, the term 'Native Americans' includes the following populations: Alaska Native, American Indian, and Native Hawaiian. The term 'Native Hawaiian' means any individual whose ancestors were natives, prior to 1778, belonging to the area that now comprises the State of Hawaii.

Studies should: be culturally appropriate and result in promoting the adoption of healthy lifestyles; improve behaviors and social conditions and/or improve environmental conditions related to chronic disease; prevent or reduce the consumption of tobacco, alcohol, and other drugs; improve mental health outcomes; reduce risk of HIV infection; improve treatment adherence and/or health-care systems adopting standards of care to improve overall quality of life.

Applications due May 14, 2018

  Simulation Modeling and Systems Science to Address Health Disparities (R01Clinical Trial Not Allowed) (Deadlines: 1/10/18; 6/6/18)

Simulation Modeling and Systems Science to Address Health Disparities (R01Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and collaborative research focused on developing and evaluating simulation modeling and systems science to understand and address minority health and health disparities.

Applications due January 10, 2018; June 6, 2018

  Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21) (Deadline: 6/14/18)

Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant (R21) applications for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum, including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Initiative, this FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods that can considerably improve acquisition, management, analysis, and dissemination of relevant data and/or knowledge.

The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed informatics method or algorithm must have a clear rationale on why it is novel and how it will benefit the cancer research field. Potential applicants who are interested in more downstream tool development, from prototyping to hardening and adaptation, should consult the other companion FOAs listed above.

Applications due June 14, 2018

  Sustained Support for Informatics Resources for Cancer Research and Management (U24) (Deadline: 6/14/18)

Sustained Support for Informatics Resources for Cancer Research and Management (U24)

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high-value informatics research resources to serve current and emerging needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on supporting activities necessary for improved user experience and availability of existing, widely-adopted informatics tools and resources. This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by companion ITCR FOAs.

The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed sustainment plan must provide clear justifications for why the research resource should be maintained and how it has benefited and will continue to benefit the cancer research field. In addition, mechanisms for assessing and maximizing the value of the resource to researchers and supporting collaboration and/or deep engagement between the resource and the targeted research community should be described.

Applications due June 14, 2018

  Testing Interventions for Health-Enhancing Physical Activity (R01 - Clinical Trial Optional) (Deadlines: 10/5/18; 6/5/19; 2/5/20; and 10/5/20)

Testing Interventions for Health-Enhancing Physical Activity (R01 - Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to fund highly innovative and promising research that tests multi-level physical activity intervention programs acting on at least two levels of the socio-ecological model and designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation. This FOA provides support for up to 5 years for research planning, intervention delivery, and follow-up activities.

Applications due October 5, 2018; June 5, 2019; February 5, 2020; and October 5, 2020

  Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3) Clinical Trials Not Allowed (Deadlines: 2/14/18; 7/10/18; and 10/8/18

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3) Clinical Trials Not Allowed

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the adoption and validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA also includes the validation of pharmacodynamic markers and markers of toxicity. Applicants to this FOA must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the assay(s) and marker(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, multiple assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously.

Applications due February 14, 2018; July 10, 2018; October 8, 2018

National Institutes of Health (NIH)

Open AllClose All
  Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) (LOI Deadline: 2/15/18; Submission Deadline: 3/15/18)

Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials that have the potential to reduce the burden of cancer through improvements in early detection, prevention, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. This FOA does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients. The proposed investigator-initiated projects should be related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences as based on their scientific missions.

LOI Deadline: February 15 Deadline: March 15, 2018

  National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) (LOI Deadline: 2/15/18; Submission Deadline: 3/15/18)

National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)

The purpose of this Funding Opportunity Announcement (FOA) is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis (DCTD). Applicants are strongly encouraged to consult the NCI DCTD website to learn more about the various program goals, research priorities, and strategies developed to fight cancer. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. Applications that propose phase III clinical trials in any area of cancer research are not sought by and will not be supported through this FOA.

LOI Deadline: February 15 Deadline: March 15, 2018

  FUSF-CRI Grant Program (Focused Ultrasound and Cancer Immunotherapy Grant Program) (Deadline: LOI 1/15/18; Application 3/1/18)

FUSF-CRI Grant Program (Focused Ultrasound and Cancer Immunotherapy Grant Program)

The Cancer Research Institute (CRI) and the Focused Ultrasound Foundation (FUSF) established a partnership in 2017 with the goal of advancing the development of new focused ultrasound (FUS) and cancer immunotherapy treatments. As a key component of the partnership, CRI and FUSF will jointly fund research through a new grant program, guided by a panel of advisors with expertise in FUS and cancer immunology/immunotherapy. The aim of the grant program is to support projects that address critical unanswered research questions that will help move the field towards new device/drug combination therapies.

This first request for proposals seeks preclinical projects to answer the following research question:

How do different "modes" of focused ultrasound (i.e. ablative vs. non-ablative, thermal vs. mechanical) compare in terms of the immune response generated, and how does this immune response correlate with biological, acoustic and imaging metrics?

The intent is to provide a detailed assessment of the FUS-induced immune response corresponding to specific sets of acoustic parameters, and also to identify biological and/or imaging metrics (e.g. MR, ultrasound) that could be more readily used in a clinical setting to signify an effective treatment. With the wide range of preclinical and clinical FUS devices being used today, it is also important that the acoustic parameters are fully described so they are translatable between systems. Deadline: Standard Dates Apply

Deadlines: LOI January 15, 2018; Application March 1, 2018

  End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness (R21/R01 Clinical Trial Optional) (Deadlines: 2/5/18; 2/16/18; 6/5/18; 6/16/18)

End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness  (R21 / R01 Clinical Trial Optional)

This funding opportunity announcement (FOA) seeks to stimulate research focused on identification of the key barriers to effective end-of-life and palliative care (EOLPC) health literacy in diverse settings and populations, and to create novel strategies, interventions, and models of care to improve EOLPC health literacy, with the goal of improving outcomes for individuals with serious, advanced illness and their families and caregivers

Deadlines:

  • Due February 5, 2018
  • Due February 16, 2018
  • Due June 5, 2018
  • Due June 16, 2018
  Palliative Care Needs of Individuals with Rare Advanced Diseases and Their Family Caregivers (Deadline: 2/5/18; 2/16/18)

Palliative Care Needs of Individuals with Rare Advanced Diseases and Their Family Caregivers

This funding opportunity announcement (FOA) seeks to expand knowledge and increase the evidence base for palliative care (PC) in advanced rare diseases, including rare cancers, and to improve physical and psychosocial well-being and quality of life among seriously ill individuals and their family caregivers.

Deadlines:

  Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (Deadline: 2/5/18; 2/16/18)

Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival

This Funding Opportunity Announcement (FOA) encourages transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available.

Because many cancer survivor populations will not experience recurrence but will die of comorbid diseases or may experience early effects of aging, inclusion of biomarkers of comorbid diseases (e.g., cardiovascular disease) and of the aging process are also sought. Applications should use experimental designs (e.g., randomized controlled clinical trials (RCTs), fractional factorial designs), and include transdisciplinary approaches that bring together behavioral intervention expertise, cancer biology, and other basic and clinical science disciplines relevant to the pathways being studied.

Deadlines

  Early-life Factors and Cancer Development Later in Life (R01/R21/R03 Clinical Trial Not Allowed) (Deadline: 2/5/18; 2/6/18; 2/16/18)

Early-life Factors and Cancer Development Later in Life (R01 / R21 / R03 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research focused on the role of early-life factors (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) in cancer development later in life. Given that the current emerging evidence from limited research indicates a potentially important role for early-life events and exposures in cancer development, it is necessary to better understand:

  1. The early-life (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) factors that are associated with later cancer development;
  2. how early-life factors mediate biological processes relevant to carcinogenesis; and
  3. whether predictive markers for cancer risk based on what happens biologically at early life can be measured and developed for use in cancer prevention strategies.

Markers that predict malignancy or pre-malignant conditions would allow assessment of early-life exposures with relevant outcomes without having to wait decades for cancer development. Ultimately, a better mechanistic understanding of how early-life events and exposures contribute to the etiology of cancer later in life will allow for the development of effective interventions during pregnancy or early life that may have a profound impact on cancer prevention.

Deadlines:

  • February 5, 2018
  • February 6, 2018
  • February 16, 2018
  Community Partnerships to Advance Research (CPAR) (R01/R21 Clinical Trial Optional) (Deadline: 2/5/18; 2/16/18; 6/5/18; 6/16/18)

Community Partnerships to Advance Research (CPAR) (R01 / R21 Clinical Trial Optional)

This funding opportunity announcement (FOA) encourages researchers to partner with community groups, using Community Engaged Research (CEnR) methodologies that will enhance relationships and lead to better intervention development and positive health outcomes.

Deadlines:

  • February 5, 2018
  • February 16, 2018
  • June 5, 2018
  • June 16, 2018
  Using Information Technology to Support Systematic Screening and Treatment of Depression in Oncology Practices (R21/R01 Clinical Trial Optional) (Deadline: 2/5/18; 2/16/18; 6/5/18; 6/16/18)

Using Information Technology to Support Systematic Screening and Treatment of Depression in Oncology Practices (R21 / R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to: identify new, information technology (IT)-enabled delivery models that support systematic screening and treatment of depression in cancer patients; test the feasibility of implementing these new delivery models in a variety of oncology practice settings, especially those serving under-served populations; and test the usability and potential effectiveness of the IT-specific components of these new delivery models.

Deadlines

  • Due February 5, 2018
  • Due February 16, 2018
  • Due June 5, 2018
  • Due June 16, 2018
  NIH Pathway to Independence Award (Parent K99/R00 - Independent Clinical Trial Required) (Deadline: 2/12/18)

NIH Pathway to Independence Award (Parent K99/R00 - Independent Clinical Trial Required)

The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers.

Deadline: February 12, 2018

  Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01 Clinical Trial Required) (Deadline: 2/14/18; 6/28/18; 10/11/18)

Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01 Clinical Trial Required)

This Funding Opportunity Announcement (FOA) is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided planning and/or execution therapy, contrast kinetic modeling, 3-D reconstruction and other quantitative tools. As many such preliminary evaluations are early in development, this FOA will provide investigators with support for pilot (Phase I and II) cancer imaging clinical trials, including patient monitoring and laboratory studies. This FOA supports novel uses of known/standard clinical imaging agents and methods as well as the evaluation of new agents, systems, or methods. The imaging and image-guided intervention (IGI) investigations, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPOREs), Cancer Centers and/or the NCI's National Clinical Trials Network.

Deadline:

  • February 14, 2018
  • June 28, 2018
  • October 11, 2018
  Population Health Interventions: Integrating Individual and Group Level Evidence (R21) - Clinical Trial Optional (Deadline: 2/16/18)

Population Health Interventions: Integrating Individual and Group Level Evidence (R21) - Clinical Trial Optional

To improve health and reduce the burden of disease, scientific research needs to be implemented at the population level in addition to the biological and clinical levels. The purpose of this funding opportunity announcement (FOA) is to support multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes.

Deadline: February 16, 2018

  Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) (Deadline: 2/28/18)

Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community.

Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are non-responsive to this solicitation and will not be reviewed.

Application Due February 28, 2018

  Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed) (Deadline: 2/28/18)

Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses.

This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.

Application Due February 28, 2018

  Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (Deadlines: 2/28/18; 5/29/18; 9/28/18)

Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications to incorporate a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program from currently funded grant (see options below). Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities.

As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

Application Due: February 28, 2018; May 29, 2018; and September 28, 2018

  Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the PDX Development and Trial Centers Research Network (PDXNet)(Admin Supp Clinical Trial Not Allowed) (Deadline: 3/1/18)

Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the PDX Development and Trial Centers Research Network (PDXNet)(Admin Supp Clinical Trial Not Allowed)

This administrative supplement funding opportunity announcement is part of the Cancer Moonshot initiative to accelerate cancer research, and was developed in response to a recommendation from the Blue Ribbon Panel of experts charged with advising the National Cancer Advisory Board on the exceptional scientific opportunities that could be accelerated through this initiative. As part of the Cancer Moonshot initiative, the National Cancer Institute (NCI) created the Patient-Derived Xenograft (PDX) Development and Trial Centers Research Network (PDXNet), a collaborative network of centers of excellence focused on using patient-derived xenografts and other patient-derived models to accelerate the development of NCI investigational new drug (IND) agents (i.e., those that the NCI is developing in collaboration with pharmaceutical partners) in NCI-sponsored early phase clinical trials.

This FOA supports supplemental funds to current NCI-funded research projects for new interdisciplinary collaborations between non-PDXNet investigators and PDXNet investigators to perform research within the scientific scope(s) of the parent grant and/or cooperative agreement award(s) that will lead to improved pre-clinical evaluations of novel therapeutic concepts using the large-scale PDX model collections of PDXNet, and that could ultimately be tested in NCI-sponsored clinical trials.

Deadline: March 1, 2018

  Health Promotion and Disease Prevention Research Centers: Special Interest Project Competitive Supplements (SIPS) (Deadline: 3/1/18)

Health Promotion and Disease Prevention Research Centers: Special Interest Project Competitive Supplements (SIPS)

This RFA will provide supplemental funding to Prevention Research Centers (PRCs) to design, test, and disseminate effective applied public health prevention research strategies to include behavioral interventions, environmental or system-wide solutions, and strategies that address major causes of disease and disability. Research strategies align with public health priorities such as the Healthy People 2020 topic areas: Epilepsy, Cancer, and Oral Health.

Deadline: March 1, 2018

  Short-term Mentored Career Enhancement Awards for Mid-Career Investigators to Integrate Basic Behavioral and Social Sciences (K18-No Independent Clinical Trials) (Deadline: 3/6/18; 3/6/19)

Short-term Mentored Career Enhancement Awards for Mid-Career Investigators to Integrate Basic Behavioral and Social Sciences (K18-No Independent Clinical Trials)

This Funding Opportunity Announcement (FOA) encourages applications for short-term mentored career development (K18) awards that improve synergies among researchers in basic and applied behavioral-social sciences, human subjects and model animals settings; and biomedical and behavioral-social sciences.

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (FOA #).

Deadline:

  • March 6, 2018
  • March 6, 2019
  Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) (Deadline: 3/15/18 or 6/5/18)

Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials that have the potential to reduce the burden of cancer through improvements in early detection, prevention, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health.

Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. This FOA does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients. The proposed investigator-initiated projects should be related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences as based on their scientific missions.

Deadline: March 15, 2018 OR June 5, 2018

  National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) (Deadline: 3/15/18 or 6/5/18)

National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)

The purpose of this Funding Opportunity Announcement (FOA) is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis (DCTD).

Applicants are strongly encouraged to consult the NCI DCTD website to learn more about the various program goals, research priorities, and strategies developed to fight cancer. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. Applications that propose phase III clinical trials in any area of cancer research are not sought by and will not be supported through this FOA.

Deadline: March 15, 2018 OR June 5, 2018

  Microphysiological Systems (MPS) for Modeling Diabetes (UG3/UH3 Clinical Trial Not Allowed) (Deadline: 3/20/18)

Microphysiological Systems (MPS) for Modeling Diabetes (UG3/UH3 Clinical Trial Not Allowed)

NIDDK requests applications to join a new research consortium "Microphysiological Systems (MPS) for Modeling Diabetes (MPS-MOD)". NIDDK will support the development and validation of human tissue chips that closely mimic the normal physiology of key metabolic tissues, including the pancreatic islet, liver, skeletal muscle, and white adipose tissue (WAT). Experimental designs for the MPS-MOD platforms should incorporate strategies to measure pathophysiological changes associated with metabolic disease, including the impact of immune cells on metabolic dysfunction. Once developed, these multi-dimensional MPS-MOD platforms will serve as the foundation for NIDDK's advanced strategy to identify new and novel therapeutics for diabetes. The utility and validity of model systems developed under this initiative will be measured, in part, through the ability of known diabetes therapeutic agents and biomarkers to influence biology of the system, using best practices and rigorous study design.

The need for high-quality, well-characterized isogenic/patient derived iPSC (induced pluripotent stem cell) lines and standardized differentiation procedures is a critical step in turning disease-specific lines into tools for discovery. In the future, iPSC-based human tissue chips could play a central role in drug development, testing, screening, drug repurposing and toxicity testing. Eventually, collections of iPSCs that capture the heterogeneity of T2D could be used to conduct "clinical trials in a dish", to discover biomarkers of response and to develop personalized treatments. An essential feature of this program will be a multidisciplinary approach that brings together basic science experts and physician scientists in stem cell biology, bioengineering, computational biology, pharmacology, liver biology, islet biology, adipose biology, metabolism and diabetes.

Deadline: March 20, 2018

  NextGen Tissue Chip Testing Centers: Validating Microphysiological Systems (U24 Clinical Trial Not Allowed) (Deadline: 3/21/18)

NextGen Tissue Chip Testing Centers: Validating Microphysiological Systems (U24 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites applications for NextGen Tissue Chip Testing Center(s) (NextGen TCTC) that will provide resources and infrastructure for the validation of tissue chips being developed as part of the NIH Tissue Chip (TC) for Drug Screening Program or NIH Microphysiological Systems (MPS) Program. The MPS program supports a consortium of investigators developing accurate cellular and organ microsystems representative of human physiology for the evaluation of drug efficacy and toxicity (RFA-RM-11-022; RFA-TR-16-017; RFA-TR-16-019). The developed in vitro MPS platforms are representative of major organs and tissues in the human body, and need to be validated for their predictive capabilities of the assessment of biomarkers, and the bioavailability, efficacy, and toxicity of therapeutic agents prior to entry into clinical trials. Validation of the tissue chips is currently being conducted through Tissue Chip Testing Centers. These are responsible for testing a select group of compounds using predefined assays and biomarkers, according to pharmaceutical industry standards, and the integration of the data into a public database.

NextGen TCTC(s) will aim to accelerate the transition of NIH-supported research innovations and technologies toward a self-sustaining model to continue the validation of various MPS platforms. NextGen TCTC(s) will develop services that promote the use of MPS by industry, regulatory bodies, and biotech sectors, and create significant value and economic stimulus or, advance the research in MPS technology in a way that could stimulate future growth and investments, and advance drug discovery and development. This U24 is intended to support research and development (R&D) specifically targeted at activities that can help address the funding gap between promising R&D and transitioning to the market, often called the “Valley of Death” by contributing the critical funding needed by applicants to pursue the next appropriate milestone(s) toward commercialization; and to foster partnerships among a variety of research and development (R&D) collaborators working toward these aims.

Deadline: March 21, 2018

  Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed) (Deadline: 3/22/18)

Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed)

As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First), the NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer cohorts to elucidate the genetic contribution to childhood cancers, or to expand the range of disorders included within the Kids First Data Resource to investigate the genetic etiology of structural birth defects. Whole genome, exome, and transcriptome sequencing are available for tumor or affected tissue when justified. These data will become part of the Gabriella Miller Kids First Pediatric Data Resource (Kids First Data Resource) for the pediatric research community.

Deadline: March 22, 2018

  Tobacco Use and HIV in Low and Middle Income Countries (Deadline: 4/4/18)

Tobacco Use and HIV in Low and Middle Income Countries

The purpose of this funding opportunity announcement (FOA) is to encourage research focused on tobacco use and human immunodeficiency virus (HIV) infection in low and middle income countries (LMICs). In particular, applications are encouraged that focus on the development and evaluation of tobacco cessation interventions tailored to HIV positive populations, including those with co-morbidities such as tuberculosis (TB), in low-resource settings in LMICs. This FOA provides funding for research planning, intervention delivery, and follow-up activities.

Deadline: April 4, 2018

  Tobacco Use and HIV in Low and Middle Income Countries (R21/R01 Clinical Trial Optional) (Deadline: 4/4/19)

Tobacco Use and HIV in Low and Middle Income Countries (R21/R01 Clinical Trial Optional)

The purpose of this funding opportunity announcement (FOA) is to encourage exploratory/developmental research focused on tobacco use and human immunodeficiency virus (HIV) infection in low and middle income countries (LMICs). In particular, applications are encouraged that focus on the development and evaluation of tobacco cessation interventions tailored to HIV positive populations, including those with co-morbidities such as tuberculosis (TB), in low-resource settings in LMICs. This FOA provides funding for research planning, intervention delivery, and follow-up activities.

Deadline: April 4, 2019

  Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R01/R21 Clinical Trial Optional) (Deadline: 4/11/18)

Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R01/R21 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) encourages transdisciplinary research that will leverage cognitive neuroscience to improve traditional measurement of cognitive impairment following cancer treatment, often referred to as "chemobrain." A better understanding of the acute- and late-term cognitive changes following exposure to adjuvant chemotherapy and molecularly-targeted treatments, including hormonal therapy, for non-central nervous system tumors can inform clinical assessment protocols with downstream implications for survivorship care plans. Deadline:

April 11, 2018

  Bioengineering Research Partnerships (U01 Clinical Trial Optional) (Deadline: 5/8/18; 9/13/18)

Bioengineering Research Partnerships (U01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical problems.  The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine.  Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies, and engage biomedical researchers or clinicians throughout the project.  The goal of the program is to support projects that can realize meaningful solutions within 5 – 10 years.

Deadline:

  • May 8, 2018
  • September 13, 2018
  Perception and Cognition Research to Inform Cancer Image Interpretation (R01/R21 Clinical Trial Optional) (Deadline: 5/30/18)

Perception and Cognition Research to Inform Cancer Image Interpretation (R01/R21 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.

Components of Participating Organizations:

  • National Cancer Institute (NCI)
  • National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Deadline: May 30, 2018

  Exploratory/Developmental Surgical Disparities Research (Deadline: 6/7/18)

Exploratory/Developmental Surgical Disparities Research

The purpose of this Funding Opportunity Announcement (FOA) is to encourage developmental and exploratory research focused on understanding and addressing disparities in surgical care and outcomes, in minority and health disparity populations. The goal is to better understand and explore effectiveness of clinical intervention approaches for addressing surgical disparities, while employing multi-level strategies at the institutional and systems level.

Deadline: Application Due June 7, 2018

  Partnership for Aging and Cancer Research (U01 Clinical Trial Not Allowed) (Deadline: 6/8/18)

Partnership for Aging and Cancer Research (U01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) is a joint effort between the National Cancer Institute (NCI) and the National Institute on Aging (NIA) to promote research that will advance current understanding of the mechanisms by which aging impacts cancer onset, progression, metastasis, and therapeutic response. To maximize collaborative interactions for this program, NIH extramural scientists will collaborate with investigators in the NCI Center for Cancer Research (NCI CCR) and/or the NIA Intramural Research Programs (NIA IRP) to address key questions on the aging contribution to cancer. These collaborating NCI CCR and NIA IRP investigators should be tenured or tenure-track scientists with whom the NIH extramural NIH scientist has made prior contact regarding the collaborative project.

Deadline: June 8, 2018

  Innovative Approaches to Studying Cancer Communication in the New Media Environment (R01/R21 Clinical Trial Optional) (Deadline: 6/13/18)

Innovative Approaches to Studying Cancer Communication in the New Media Environment (R01/R21 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) invites applications that seek to apply one or more innovative methodologies in communication research across the cancer control continuum, from prevention, early detection, diagnosis, treatment, and survivorship, to end of life. Applications to this FOA should utilize one or more of the following analytic approaches, methods, and data sources, including but not limited to social media data mining, Natural Language Processing (NLP) techniques, online social network analysis, crowdsourcing research tools (e.g., mTurk), online search data, Ecological Momentary Assessment, neuroscience and biobehavioral approaches to communication, and geographic information systems. Studies should assess outcomes related to cancer prevention and control (e.g., knowledge, attitudes, beliefs, perceived risk, decision making in screening and treatment, information inequalities, social support, shared decision making, persuasion, caregiving, behavioral intentions, preventive behaviors, and policy support, among others).

Deadline: June 13, 2018

  Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional) (Deadline: 6/15/18)

Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) allows appointment of Scholars proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary study to an existing trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

Application due June 15, 2018

  Image-guided Drug Delivery (R01 Clinical Trial Optional) (Deadline: 6/21/18)

Image-guided Drug Delivery (R01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) will support innovative research projects that are focused on image-guided drug delivery (IGDD), including real-time image guidance, monitoring, quantitative in vivo characterizations and validation of delivery and response. It will support research in development of integrated imaging-based systems for delivery of drugs or biologics in cancer and other diseases, quantitative imaging assays of drug delivery, and early intervention.

Application due June 21, 2018

  Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01/R21 Clinical Trial Optional) (Deadline: 6/27/18)

Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01/R21 Clinical Trial Optional)

The purpose of this funding opportunity announcement is to support studies on electronic nicotine delivery systems (ENDS) that examine population-based, clinical and applied prevention of disease, including etiology of use, epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations.

Deadline: June 27, 2018

  NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) (Deadline: 7/19/18)

NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)

The purpose of this Funding This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials.

The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk, but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical).

Deadline: July 19, 2018

  Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) (Due Dates Vary by Awarding IC)

Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

The National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for administrative supplements are considered prior approval requests (as described in Section 8.1.2.11 of the NIH Grants Policy Statement) and will be routed directly to the Grants Management Officer of the parent award.

Deadline: Due dates vary by awarding IC

  NCI Transition Career Development Award to Promote Diversity (Deadline: Standard Dates Apply)

NCI Transition Career Development Award to Promote Diversity

The purpose of the NCI Transition Career Development Award to Promote Diversity is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist.

Deadline: Standard Dates Apply

  Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional) (Deadline: Standard Dates Apply)

Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)

The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.

Deadline: Standard Dates Apply

  Cancer Research Education Grants Program - Curriculum or Methods Development (R25) (Deadline: Standard Dates Apply)

Cancer Research Education Grants Program - Curriculum or Methods Development (R25)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Curriculum or Methods Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

Deadline: Standard Dates Apply

  Cancer Research Education Grants Program - Research Experiences (R25) (Deadline: Standard Dates Apply)

Cancer Research Education Grants Program - Courses for Skills Development (R25)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

Deadline: Standard Dates Apply

  Cancer Research Education Grants Program - Research Experiences (R25) (Deadline: Standard Dates Apply)

Cancer Research Education Grants Program - Research Experiences (R25)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

Deadline: Standard Dates Apply

  Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01 Clinical Trial Optional) (Deadline: Standard Dates Apply)

Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support projects that will elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based therapies for pain.

Deadline: Standard Dates Apply

  Education and Health: New Frontiers (Deadline: Standard Dates Apply)

Education and Health: New Frontiers

The goal of this funding opportunity announcement is to support research that will further elucidate the pathways involved in the relationship between education and health outcomes and in doing so to carefully identify the specific aspects and qualities of education that are responsible for this relationship and what the mediating factors are that affect the nature of the causal relationship.

Deadline: Standard Dates Apply

  End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (Deadline: Standard Dates Apply)

End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses

The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12 – 24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.

Deadline: Standard Dates Apply

  Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) (Deadline: Standard Dates Apply)

Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.

Deadline: Standard Dates Apply

  Integrative Research on Polysubstance Abuse and Addiction (R21/R33 Clinical Trial Optional) (Deadline: Standard Dates Apply)

Integrative Research on Polysubstance Abuse and Addiction (R21/R33 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) is supported by Collaborative Research on Addiction (CRAN) at the National Institutes of Health (NIH), a trans-NIH partnership composed of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Drug Abuse (NIDA), and the National Cancer Institute (NCI). The intent of this FOA is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies. These dual objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, where polysubstance research can occur in any of these translational stages during the R21 phase and these findings will be rapidly back- or forward-integrated into another stage during the R33 phase, allowing for bi-directional research exchange.

Deadline: Standard Dates Apply

  Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (Deadline: Standard Dates Apply)

Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake

This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.

Deadline: Standard Dates Apply

  Mechanisms, Models, Measurement, & Management in Pain Research (R21 Clinical Trial Optional) (Deadline: Standard Dates Apply)

Mechanisms, Models, Measurement, & Management in Pain Research (R21 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to inform the scientific community of the pain research interests of the various Institutes and Centers (ICs) at the National Institutes of Health (NIH) and to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioral and social sciences. Although great strides have been made in some areas, such as the identification of neural pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and unsolved. Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute injury is limited. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators.

Deadline: Standard Dates Apply

  Mentored Clinical Scientist Research Career Development Award (Deadline: Standard Dates Apply)

Mentored Clinical Scientist Research Career Development Award

The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.

Deadline: Standard Dates Apply

  Methodology and Measurement in the Behavioral and Social Sciences (Deadline: Standard Dates Apply)

Methodology and Measurement in the Behavioral and Social Sciences

The purpose of this Funding Opportunity Announcement (FOA) is to invite qualified researchers to submit grant applications aimed at improving and developing methodology in the behavioral and social sciences through innovations in research design, measurement, data collection and data analysis techniques.

The participating NIH Institutes and Centers (ICs) encourage research that will improve the quality and scientific power of behavioral and social science data relevant to the IC missions. Applicants are strongly encouraged to contact the Scientific/Research Contact (see Section VII, Agency Contacts) of the IC that most closely matches their research focus to determine IC interest in the proposed research topic.

Deadline: Standard Dates Apply

  NCI Mentored Research Scientist Development Award to Promote Diversity (K01) (Deadline: Standard Dates Apply)

NCI Mentored Research Scientist Development Award to Promote Diversity (K01)

The purpose of the NCI Mentored Research Scientist Development Award (K01) is to enhance the diversity of the pool of the NCI-funded cancer research workforce by supporting eligible individuals from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor.

The Diversity Training Branch (DTB) of the Center to Reduce Cancer Health Disparities (CRCHD), at the National Cancer Institute (NCI), invites career development award applications (K01) from individuals from backgrounds that have been shown to be nationally underrepresented in health-related sciences.

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOA.

Deadline: Standard Dates Apply

  NCI Small Grants Program for Cancer Research (NCI Omnibus R03 Clinical Trial Optional) (Deadline: Standard Dates Apply)

NCI Small Grants Program for Cancer Research (NCI Omnibus R03 Clinical Trial Optional)

This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.  

Deadline: Standard Dates Apply

  Population Health Interventions: Integrating Individual and Group Level Evidence (Deadline: Standard Dates Apply)

Population Health Interventions: Integrating Individual and Group Level Evidence

To improve health and reduce the burden of disease, scientific research needs to be implemented at the population level in addition to the biological and clinical levels. The purpose of this funding opportunity announcement (FOA) is to support multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes.

Deadline: Standard Dates Apply

  Research Supplements to Promote Diversity in Health-Related Research (Due Dates Vary by Awarding IC)

Research Supplements to Promote Diversity in Health-Related Research (Admin Supp)

The National Institutes of Health (NIH) hereby notify Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) holding specific types of research grants (activity codes listed above) that funds are available for administrative supplements to improve the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from groups that have been shown to be underrepresented in health-related research. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project. Administrative supplements must support work within the scope of the original project.

Deadline: Due dates vary by awarding IC

  Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32) (Deadline: Standard Dates Apply)

Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)

The National Institutes of Health (NIH) will award Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32) to eligible, domestic institutions to enhance predoctoral and postdoctoral research training, including short-term research training, and help ensure that a diverse and highly trained workforce is available to meet the needs of the Nation’s biomedical, behavioral, and clinical research agenda. Research training programs will incorporate didactic, research, and career development elements to prepare individuals for careers that will have a significant impact on the health-related research needs of the Nation. Programs proposing only short-term research training should not apply to this announcement, but rather to the Kirschstein-NRSA Short-Term Institutional Research Training Grant Program (T35) exclusively reserved for predoctoral, short-term research training.

Deadline: Standard Dates Apply

  Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional) (Deadline: Standard Dates Apply)

Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. Research can involve any aspect of the cancer continuum and any phase of the translational spectrum.

Deadline: Standard Dates Apply

  Target Assessment, Engagement and Data Replicability to Improve Substance Use Disorders Treatment Outcomes (R21/R33 Clinical Trial Optional) (Deadline: Standard Dates Apply)

Target Assessment, Engagement and Data Replicability to Improve Substance Use Disorders Treatment Outcomes (R21/R33 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) is part of an NIH initiative known as Collaborative Research on Addiction at NIH (CRAN). Areas supported by this FOA include research to generate and conduct preliminary tests of targeted addiction treatment to address multiple substances, which may include alcohol, tobacco and other drug use (ATOD).

This FOA encourages applications that focus on early-stage, treatment generation and pilot clinical trials that are consistent with an experimental therapeutic approach. This approach requires the identification of a theory-derived target based on putative mechanisms of alcohol, tobacco and other drug use, and clear hypotheses about how a treatment directed at changing the target can lead to clinical benefits.

Studies of novel treatments include, but are not limited to behavioral, pharmacological, physiological, learning- and device-based treatment approaches. This FOA provides support for up to two years (Phase I; R21) for protocol development, target identification and studies to confirm target engagement (i.e., link targets with tangible outcomes); followed by up to 3 years of support (Phase II; R33) for replication studies of addiction treatment across 2 or more settings. Specifically, this latter phase will focus on clinical trials that apply the target in a treatment setting (development, refinement, and/or adaptation) to evaluate the feasibility of conducting a larger trial.

Deadline: Standard Dates Apply

  The Health of Sexual and Gender Minority (SGM) Populations (Deadline: Standard Dates Apply)

The Health of Sexual and Gender Minority (SGM) Populations

The National Institutes of Health (NIH) is committed to supporting research that will increase scientific understanding of the health status of diverse population groups and thereby improve the effectiveness of health interventions and services for individuals within those groups. Priority is placed on understudied populations with distinctive health risk profiles. This funding opportunity announcement (FOA) focuses on sexual and gender minority (SGM) populations, including lesbian, gay, bisexual, transgender, and intersex populations. Basic, social, behavioral, clinical, and services research relevant to the missions of the sponsoring Institutes and Centers may be proposed.

Deadline: Standard Dates Apply

  The NCI Transition Career Development Award (Deadline: Standard Dates Apply)

The NCI Transition Career Development Award

This Funding Opportunity Announcement (FOA) supports an NCI program that facilitates the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position.

Deadline: Standard Dates Apply

  Time-Sensitive Obesity Policy and Program Evaluation (R01)

Time-Sensitive Obesity Policy and Program Evaluation (R01)

This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding.

All applications to this FOA must demonstrate that the evaluation of an obesity related policy and /or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications in response to this time-sensitive FOA are not eligible for resubmission. It is intended that eligible applications selected for funding will be awarded within four months of the application due date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.

Applications due on a continuous basis (once per month)

Department of Defense (DOD)

Foundations & Organizations

Open AllClose All
  Graduate Training in Disparities Research (GTDR) | Komen for the Cure, Susan G. (Deadline: TBA)

Graduate Training in Disparities Research (GTDR) | Komen for the Cure, Susan G.

Graduate Training in Disparities Research (GTDR) Grants are intended to establish and/or to sustain a training program for graduate students who are seeking careers dedicated to understanding and eliminating disparities in breast cancer outcomes across population groups.

By providing funding to outstanding training programs, Komen seeks to ensure that a diverse pool of highly trained scientists will emerge as the next generation of leaders in the field of breast cancer research focused on disparities in breast cancer outcomes.

The research training program should be designed to meet the following goals:

  • Attract graduate students, specifically those from populations affected by disparities in breast cancer outcomes, into research careers.
     
  • Empower these students with the skills and knowledge necessary to effectively explore the causes of differential breast cancer outcomes and develop interventions to reduce and eliminate such disparities.

Deadline TBA

  Distinguished Scholars | Lustgarten Foundation

Distinguished Scholars | Lustgarten Foundation

The Distinguished Scholars program supports world-class scientists, who are at the top in their field, and are at the forefront of today's most exciting breakthroughs in pancreatic cancer research. Selected by The Lustgarten Foundation's Scientific Advisory Board (SAB), each grantee will receive $5 million in funding over the next five years, enabling these scientists to purse high-risk high-reward science, dedicate more of their time and focus to pancreatic cancer research, and accelerate a path to a cure.

The Distinguished Scholar Award is given on a discretionary basis and is not part of the annual grant program.

  Komen Southeast Wisconsin's Small Grant Program

Komen Southeast Wisconsin's Small Grant Program

Any non-profit organization in the Komen Southeast Wisconsin service area can apply for up to $5,000 for a small pilot or capacity-building breast health program grant. These grants are for organizations interested in beginning a new program or testing new ideas that will increase the innovative capacity and effectiveness of breast health programs that serve low income and uninsured women.

Small Grants are available in two categories:

  1. Education/Outreach Grants will support the development of breast cancer programs or projects.
     
  2. Capacity Building/Technical Assistance Grants will provide funding to increase the efficiency and effectiveness of an organization's ability to provide services by redesigning processes, implementing new practices, or developing collaborations or partnerships.

Applications due on a continuous basis throughout funding cycle

  Pediatric Low Grade Astrocytomas Foundation (PLGA)(Applications continuous)

Pediatric Low Grade Astrocytomas Foundation (PLGA)

The number one priority of A Kids' Brain Tumor Cure Foundation is to act as a catalyst for researchers world-wide to turn their attention to the area of pediatric low grade glioma brain tumor research and to award research grants for the most promising programs and studies. The hope is that this research will lead to a better understanding of the causes of PLGA as well as the discovery of more effective treatments and a cure for the most common forms of children's brain tumors.

Proposals related to basic and translational* projects that can advance understanding of the underlying biology of the development and treatment of PLGA tumors will be considered.

*NIH definition of translational research: the process of applying ideas, insights, and discoveries generated through basic scientific inquiry to the treatment or prevention of human disease.

Applications continuous

  SWOG Trial Support (STrS) – The Hope Foundation (Applications continuous)

SWOG Trial Support (STrS) – The Hope Foundation

SWOG's mission is to improve the practice of cancer medicine in preventing, detecting, and treating cancer, and to enhance the quality of life for cancer survivors, primarily through design and conduct of clinical trials. SWOG is a National Cancer Institute-supported network of more than 5,000 cancer researchers at more than 650 institutions in the U.S., Canada, and beyond. Additional educational and cancer research support is provided by SWOG's non-profit, philanthropic partner, The Hope Foundation.

STrS is a peer-reviewed program administered by The Hope Foundation in conjunction with SWOG. STrS is designed to support trial components that need supplemental funding during patient enrollment in a SWOG study. Qualifying components may include things that are outside of the SWOG-supported norm, such as atypical requests for tissue and/or data, or provision of materials to trial sites.

Applications continuous

Pancreatic Cancer Action Network

Institutional

Other

Open AllClose All
  Kure It-AACR Research Grant for Immunotherapy in Kidney Cancer (Deadline: 2/19/18)

Kure It-AACR Research Grant for Immunotherapy in Kidney Cancer

The AACR-Kure It Research Grant for Immunotherapy in Kidney Cancer represents a joint effort to promote and support innovative cancer research. This grant is available to full time, independent junior and senior investigators to study immunological aspects of, or treatments for, kidney cancer. Research projects should advance the basic knowledge of tumor immunology mechanisms, or develop new concepts in the treatment, control, or prevention of kidney cancer by immunology-based therapeutic approaches. Proposed projects may be basic, translational, clinical, or epidemiological in nature and must focus on cancer immunology including, but not limited to: immune recognition, regulation, tumor escape, and therapeutic manipulation for kidney cancer.

Deadline: February 19, 2018

  Collaborative Pediatric Cancer Research Awards Program (Deadline: 2/22/18)

Collaborative Pediatric Cancer Research Awards Program

Rally funds research in the following areas:

  • Under-studied cancer types
  • Innovative approaches to childhood cancer research which could lead to advanced studies or clinical trials
  • Studies that are likely to lead to a clinical trial, personalized, alternative, or integrated research proposals
  • Quality of life and survivorship research proposals

Full proposals due February 22, 2018

  AACR-Johnson & Johnson Lung Cancer Innovation Science Grants (Deadline: 3/2/18)

AACR-Johnson & Johnson Lung Cancer Innovation Science Grants

Because of the late onset of clinical symptoms and inadequate screening programs, nearly two-thirds of all lung cancers are diagnosed at an advanced stage and, as a result, five-year survival rates are still below 18%. Interventions at the earliest stages of the disease process while there are no clinical manifestations, or when the tumor is small and localized, improves survival outcomes; therefore, simple yet accurate diagnostic tools that can improve the detection of early lung cancers are urgently needed.

The AACR-Johnson & Johnson Lung Cancer Innovation Science Grants represent a joint effort to address this need by promoting and supporting pioneering cancer research. Proposals should focus on understanding the behaviors that lead to chronic exposures to respiratory carcinogens and how these behaviors can be modified; how chronic exposures produce cellular/genomic damage and how these can be ameliorated; deciphering the types of inflammation that underlie the carcinogenic process; understanding the alterations in innate and adaptive immunity that create an immune-permissive microenvironment; and changes in the pulmonary microbiome that may contribute to carcinogenesis. Proposals that characterize premalignant lesions or that substantially improve the detection of lung cancer at more curable stages will also be prioritized.

This project must be implemented by a multi-institutional team, composed of Principal Investigators from at least two, but no more than three, different institutions. The Grant will provide $1.5 million in funding for direct and indirect expenses related to each research project over a three year timeframe.

In addition to the grant, the AACR will provide strategic project management support to help optimize project implementation and progress during the grant term.

Deadline: March 2, 2018

  Investigator Award in Cell and Gene Therapy for Cancer (Deadlines: 3/13/18-Abstract; 5/15/18-Application)

Investigator Award in Cell and Gene Therapy for Cancer

Alliance for Cancer Gene Therapy, Inc. (ACGT) funds research aimed at furthering the development of cell and gene therapy approaches to the treatment of cancer.

This award is for those conducting cell and gene therapy research in the following areas:

  • Technology for systemic delivery and treatment of metastatic disease that could involve novel tumor-targeted delivery vehicles (e.g. tumor-homing cells, nanoparticles and new recombinant viruses).
  • Altering the tumor cell microenvironment to support the induction of anti-tumor immunity
  • Identification of novel tumor targets
  • Novel approaches to either protective adoptively transferred cells from metabolic changes or alter the metabolism of transferred cells.


Preference will be given to those working in solid tumors, orphan tumors or pediatric tumors, and to research not previously funded, thus highly innovative proposals.

Deadline: March 13, 2018 (Abstract) May 15, 2018 (Application)

  Childhood Cancer Research Seed Grants (Deadline: LOI due 10/19/17; Applications due 3/15/18)

Childhood Cancer Research Seed Grants

The Foundation invites applications for its seed grant program, which provides funding to conduct innovative, cutting edge investigations, with preferences going toward less common childhood cancers. In addition, more projects that focus on Opsoclonus-Myoclonus Syndrome (OMS) will be considered.

The Foundation is interested in principal investigators who will join it in taking risks, pushing for new solutions, and harnessing the transformative power of science in their research in the following broad areas:

  • Mechanisms of Disease
  • Genetics
  • Preclinical Models
  • Biomarkers and Surrogate Markers
  • Prognostic Factors
  • Diagnosis
  • Innovative Clinical Therapeutic Trials
  • Minimal Residual Disease Detection
  • Treatment
  • Supportive Care and Prevention
  • Amelioration of Long-Term Effects of Therapy

By seeking answers and adding to the body of knowledge in pediatric cancer research, The Pablove Foundation will make an impact on the lives of children who are affected by childhood cancer.

LOI Due October 19, 2017, Applications due March 15, 2018

  Damon Runyon-Sohn Pediatric Cancer Fellowship Award (Deadline: 3/15/18)

Damon Runyon-Sohn Pediatric Cancer Fellowship Award

The Damon Runyon Cancer Research Foundation has joined together with the Sohn Conference Foundation, dedicated to curing pediatric cancers, to establish the Damon Runyon-Sohn Pediatric Cancer Fellowship Award. This award provides funding to basic scientists and clinicians who conduct research with the potential to significantly impact the prevention, diagnosis or treatment of one or more pediatric cancers.

Candidates must apply for the fellowship under the guidance of a Sponsor. In addition to aiding in the planning, execution and supervision of the proposed research, the Sponsor's role is to foster the development of the Fellow's overall knowledge, technical and analytical skills, and capacity for scientific inquiry. The Sponsor is also expected to assist the Fellow in attaining his/her career goals.

The proposed research and training environment should represent a new opportunity for the candidate to expand his/her scientific skill set. Direct extensions of the candidate's graduate work (in approach, technique or exact area of study) will not be funded.

Postdoctoral training in the same institution in which the applicant received his/her degree is discouraged, particularly if it is in the same department.

Deadline: March 15, 2018

  CBTF Research Grants (Deadline: 3/19/18)

CBTF Research Grants

The Childhood Brain Tumor Foundation (CBTF) is soliciting grant applications for the calendar year 2018. There will be two categories of awards:

Pediatric Brain Tumor Grant Awards

Our standard grant request for pediatric brain tumor awards will continue as usual. We anticipate funding up to two (2) research proposals that are a maximum of two years in duration. Funding requests cannot exceed $30,000/year or a maximum of $60,000 over the course of the award.

Diffuse Intrinsic Pontine Glioma (DIPG) Research Award

We have specific funds for one, 1-year research proposal related to DIPG. The funding request for this award can be up to a maximum of $45,000.

Deadline: March 19, 2018

  Prostate Cancer Foundation Young Investigator Awards (Deadline: 3/19/18)

Prostate Cancer Foundation Young Investigator Awards

PCF Young Investigator Awards will be three (3) years in duration and will provide $75,000 per year. The award funds may be used flexibly to advance the career and research efforts of the awardee. This for example, includes funding "protected time" or direct costs for laboratory science. Every PCF Young Investigator is required to be under the direct supervision of a mentor. Young Investigator awardees are required to attend the Annual PCF Scientific Retreat and Young Investigator Day, typically held in October, throughout the duration of their award and beyond.

Deadline: March 19, 2018

  Innovation Grant (Alex’s Lemonade Stand Foundation for Childhood Cancer) (Deadline: 4/2/18)

Innovation Grant (Alex’s Lemonade Stand Foundation for Childhood Cancer)

The Innovation Grant is designed to provide critical and significant seed funding for experienced investigators with a novel and promising approach to finding causes and cures for childhood cancers.

Applications due April 2, 2018

  National Partnerships to Promote Cancer Surveillance Standards and Support Data Quality and Operations of National Program of Cancer Registries (R01/R21 Clinical Trial Optional) (Deadline: 4/20/18)

National Partnerships to Promote Cancer Surveillance Standards and Support Data Quality and Operations of National Program of Cancer Registries (R01/R21 Clinical Trial Optional)

Since the passage of the Cancer Registries Amendment Act in 1992, Centers for Disease Control and Prevention (CDC) supports the collection of cancer surveillance data through the National Program of Cancer Registries (NPCR). Cancer registries in 47 states, the District of Columbia, Puerto Rico, the U.S. Pacific Island Jurisdictions, and the U.S. Virgin Islands collect, consolidate, and submit data on cancer occurrence, extent, treatment and outcomes of all newly diagnosed cancers. These data represent 97% of the U.S. population. CDC has established successful partnerships with national organizations to define standardized cancer surveillance practices in the U.S. and assure complete, timely, and high-quality data for the official federal U.S. Cancer Statistics.

The purpose of this Notice of Funding Opportunity (NOFO) is to fund national organizations with demonstrated expertise and capacity in cancer surveillance to enhance NPCR's data quality and operational efficiency. This program will support up to three organizations involved directly in cancer surveillance to focus on one of three essential components: 1) Education, Standards and Translation of cancer surveillance best practices; 2) Cancer Staging Collaboration and Implementation; and 3) Standardization and Support for Laboratory and Biomarker Electronic Reporting.

The overarching goal of this project is to collaboratively define and promote uniform standards in cancer staging, collection and reporting. Funded entities will identify and address specific enhancement needs of cancer registries to attain the following outcomes: increased timeliness, completeness, and quality of data reported to NPCR; increased competency of NPCR central cancer registry staff; enhanced interoperability of NPCR software; and increased electronic submission of laboratory data to NPCR registries.

Deadline: April 20, 2018

  Surgical Disparities Research (R01) (Deadline: 6/7/18)

Surgical Disparities Research (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and collaborative research focused on understanding and addressing disparities in surgical care and outcomes, in minority and health disparity populations. While the goal is to better understand and explore effectiveness of clinical intervention approaches for addressing surgical disparities, this initiative will also seek to identify multi-level strategies at the institutional and systems level.

Applications due June 7, 2018

  Stand Up To Cancer (SU2C) Dream Team Translational Research Grant (Deadline: Invited Full Proposal by 1/16/18; LOI by 9/5/17)

Stand Up To Cancer (SU2C) Dream Team Translational Research Grant

The Stand Up To Cancer Dream Team Translational Research Grant will fund a translational cancer research project that will address critical problems in patient care, including prevention strategies for those at risk, and deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional, collaborative Dream Team of expert investigators.

The ideas may focus on particular organ sites, patient populations (such as pediatrics) or on innovative methods of treatment. Projects must be designed to accelerate the application of new preventive, diagnostic or therapeutic approaches to the clinic (i.e., lead to patient involvement within 2-3 years from the beginning of the grant). Proposals for Dream Team research projects must present plans indicating how the work will be translated into the clinic. The ideas should be based on perceived opportunities for success as well as high-priority areas with a critical need for rapid progress beyond current medical care.

LOI due September 5, 2017

Invited full proposals due January 16, 2018

  Adenoid Cystic Carcinoma Research Foundation (Deadline: Continuous)

Adenoid Cystic Carcinoma Research Foundation

Adenoid Cystic Carcinoma (ACC) is a rare malignancy of secretory glands, typically originating in the salivary glands though it does appear in other primary sites, including the palate, nasopharynx, tongue base, larynx, trachea, lacrimal gland, breast and vulva. There are approximately 1,200 new cases of ACC diagnosed each year in the United States, about 60% of which involve women. This cancer has a slow, and sometimes relentless, progression characterized by frequent recurrences and metastases to sites such as the lungs, liver and bones.

Deadline continuous

  Boehringer Ingelheim Pharma GmbH & Co. KG | Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) (Deadline: Continuous)

Boehringer Ingelheim Pharma GmbH & Co. KG | Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI)

Medical Educational Grants are independent educational activities that utilize effective educational methods to address unmet medical needs that leads to improved patient outcomes. A Boehringer Ingelheim Pharmaceuticals, Inc. medical educational grant is designed to provide support for accredited educational programs for health care providers and non-accredited educational programs directed toward the patient and the local health care community.

The Medical Education Grants Department consists of education professionals who facilitate lifelong learning for clinicians and patients through support of independent education. BIPI's Medical Education and Research Grants department is committed to supporting innovative, high quality, independent medical education and research for healthcare professionals and patients that resolves unmet medical needs, fosters clinical excellence, and measurably improves health outcomes in areas of strategic focus to BIPI.

The sponsor considers funding of activities in many therapeutic areas including:

  • Therapeutic Areas Cardiovascular Disease – Stroke Prevention in Atrial Fibrillation
  • Cardiovascular Disease – Venous Thromboembolism (VTE)
  • Immunology – General Immunology
  • Oncology – Acute Myeloid Leukemia (AML)
  • Oncology – Lung Cancer
  • Respiratory Disease – Chronic Obstructive Pulmonary Disease (COPD)
  • Respiratory Disease – Interstitial Lung Disease (ILD)

Funding may be limited or exhausted in some therapeutic areas. BIPI will review and consider support of those requests in the areas above. To that end, educational objectives have been identified that are derived from evidence based science and are intended to close gaps in research, knowledge, or behaviors that represent barriers in care and patient outcomes.

Deadline continuous

  UICC Technical Fellowships (UICC-TF) [previously Global Education and Training Initiative (GETI): International Cancer Technology Transfer Fellowships (ICRETT)] (Deadline: Continuous)

UICC Technical Fellowships (UICC-TF) [previously Global Education and Training Initiative (GETI): International Cancer Technology Transfer Fellowships (ICRETT)]

The aim of the UICC ICRETT fellowships is to facilitate rapid international transfer of cancer research and clinical technology, exchange knowledge and enhance skills in basic, clinical, behavioural and epidemiological areas of cancer research cancer control and prevention and to acquire appropriate clinical management, diagnostic and therapeutic expertise for effective application and use in the home organization upon return.

  • Research plan
    • Cancer prevention and control (including tobacco control)
    • Basic, applied and clinical cancer research Epidemiology,
    • Cancer registration, public education and behavioral sciences
  • Clinical training
    • Surgery, radio and chemotherapy, medical oncology, multidisciplinary cancer care
    • Clinical trials
    • Detection and diagnosis Prevention-oriented projects are especially encouraged

Deadline Continuous

  Sanofi-Aventis U.S. Inc. Education Grants (Deadline: Continuous)

Sanofi-Aventis U.S. Inc. Education Grants

Sanofi US is committed to funding high quality educational activities and materials in the therapeutic areas of interest to the company that have the potential to improve patient care and health outcomes.

The purpose of an educational grant is to support an activity that encourages an educational interchange with respect to available scientific and medical information. Educational activities may or may not be accredited.

Educational Grants fund educational activities and materials designed to improve the knowledge, competence (skill) and/or performance of healthcare professionals, patients, and/or consumers for improved patient care and outcomes.

Grants may be given for live educational activities, as well as educational publications and other types of enduring materials (e.g. interactive web, CD rom, audio tapes, etc.) provided that the activities or materials are advertised and open to a broad audience beyond members of the requesting institution. Fellowships or career development awards may be considered in limited circumstances.

Applicant must select one of the following Therapeutic Areas:

  • Cardiovascular
  • Diabetes
  • Genetic Diseases
  • Immunology
  • Multiple Sclerosis
  • Oncology
  • Orthopedics
  • Renal
  • Thyroid Cancer
  • Transplantation

Deadline continuous

  Women's Cancer Research Grants (Deadline: Continuous)

Women's Cancer Research Grants

The FWC continues to seek additional funding to support expanded research priorities. Of special importance is increased funding for cervical, uterine, primary peritoneal, vaginal and vulvar cancer research. Additionally, the Foundation is seeking funding for a series of new types of research opportunities:

  • Post-Doctoral Fellowship grants: These grants are intended to attract and support promising young scientists and clinician/scientists to ensure the next generation of skilled researchers dedicated to gynecologic cancer research.
  • Career Development Awards: These grants are similar to the NIH CDA, K series awards, and are awarded to applicants who wish to further develop their careers in gynecologic cancer biomedical, behavioral or clinical research
  • Paired grants: Junior investigators would join with senior investigators for grants lasting two to three years.
  • Innovative grants: These grants would provide funding for creative and imaginative research projects that show promise for significant breakthroughs, but have not been sufficiently advanced or developed to receive support through traditional funding channels.
  • Extension of the current, highly successful stimulus or “seed” grant program to include all gynecologic cancers, and the opportunity for competitive renewals at the conclusion of the one-year research grant.

Deadline continuous

Other Peer Review

Top